ArticleMalaria journal2026
A prime-and-trap vaccination strategy to evaluate minimal requirements for malaria liver stage protection in mice.
Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe Plasmodium liver stage is an attractive prophylactic vaccine target since blocking parasites in the liver has the potential to prevent both clinical disease and transmission. However, immunity to Plasmodium liver stages is difficult to study, and highly efficacious liver stage vaccines have been difficult to develop. Prime-and-trap vaccination induces liver CD8
methodsIn this study, a prime-and-trap vaccination strategy was used to evaluate minimal vaccine requirements for malaria liver stage protection in mice. Here, Prime-and-trap pulls and traps primed Plasmodium yoelii circumsporozoite protein (CSP)-specific CD8
resultsPrime-and-HDT trap induced sterile protection against sporozoite challenge with CSP-HDT doses as low as 5 ng DNA. However, protection was lost at an ultra-low CSP-HDT dose of 50 pg, which was associated with a similarly low level of CSP-specific CD8
conclusionsOverall, these studies indicate that prime-and-HDT trap vaccination offers a tractable new strategy to study immunity to liver stage malaria in mice that is inexpensive, reproducible, and accessible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.